Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00674219 · ClinicalTrials.gov registry record · Phase 3

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

A Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 3
Development phase
17
Enrollment target
1
Study location

NCT00674219 is a Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00674219, a Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 3
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Because glutamatergic hyperactivity in frontal and frontal-subcortical circuits may play a role in the symptomatic expression of OCD, and possibly GAD, agents that reduce glutamatergic neurotransmission should provide unique anti-stress and anti-obsessional benefits. Memantine is a specific, uncompetitive antagonist at the NMDA receptor that blocks sustained activation of the NMDA receptor by high concentrations of glutamate under pathological conditions but rapidly leaves the NMDA channel upon transient physiological activation by low concentrations of glutamate.

Conditions Studied

Obsessive - Compulsive Disorder Generalized Anxiety Disorder

Interventions

  • DRUG Memantine

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2005-05
Est. Completion 2008-01
Phase Phase 3

Sponsor

University of California, Los Angeles

897 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00674219

The ClinicalTrials.gov registry entry for NCT00674219 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.

NCT00674219 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00674219 about?

NCT00674219 is a clinical study titled "Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder". The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Because glutamatergic hyperactivity in frontal and frontal-su...

What is the current status of trial NCT00674219?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2005-05. Estimated completion is 2008-01.

What conditions does trial NCT00674219 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, Generalized Anxiety Disorder.

What interventions are being tested in trial NCT00674219?

The interventions under investigation include: Memantine (DRUG).

Who is sponsoring clinical trial NCT00674219?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00674219 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obsessive - Compulsive Disorder

All registered trials for this condition

Generalized Anxiety Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.